Managing Director: Alan Fields, CFA, CAIA
Strategy Focus: Hedge Funds, Private Equity, Private Credit, Direct Deals
Geographic Coverage: North America
Alan Fields, CFA, CAIA | Managing Director
Alan Fields is the Managing Director at Engild Private Capital (“Engild”). Mr. Fields has over 20 years experience as an institutional sales professional, introducing investment solutions to institutional clients across a wide range of alternative products. Prior to founding Engild, he was a Principal at The Abraaj Group, where he covered fundraising and investor relations across North America. Prior to joining The Abraaj Group, he was a Managing Director with PineBridge Investments (and its predecessor entity AIG Investments). Mr. Fields has successfully raised over one billion in fund commitments in various private capital strategies including venture, growth, buyout, secondaries, emerging markets, infrastructure, and hedge funds. Prior to AIG/Pinebridge Mr. Fields was a Managing Director in institutional fixed income sales with Bear Stearns & Co, and before that he was with the auditing team of KPMG (f/k/a Peat Marwick & Mitchell).
Mr. Fields received his MBA in Finance from The Wharton School, University of Pennsylvania and a BA in Accounting from Pace University. He holds both the Chartered Financial Analyst (CFA) and Chartered Alternative Investment Analyst (CAIA) designations. He is also a Certified Public Accountant (CPA). Mr Fields currently holds the Series 3, 7, and 63 registrations with FINRA.
Carlton Holmes | Managing Director
Carlton Holmes is a Managing Director at Engild Private Capital who works closely with Engild’s founder and Managing Partner, Alan Fields, CFA, CAIA.
Prior to Engild Private Capital, Mr. Holmes was a principal at TACK37 Consulting where he provided consulting services to consumer goods companies, specializing in marketing and sales. Prior to TACK37 Consulting, Mr. Holmes was Vice President of OTC Marketing for Taro Pharmaceuticals where he grew an entire portfolio of profitable OTC generic /private label products. Prior to Taro Pharmaceuticals, Mr. Holmes was a Group Product Manager at Block Drug. Prior to Block Drug, Mr. Holmes served as a Product Manager for Johnson & Johnson.
Mr. Holmes received his MBA with a concentration in Marketing & Finance from Columbia Business School and he received his BA with a major in Mathematics and a minor in Economics from Cornell University. Mr. Holmes served as a Board Member of the Sag Harbor Hills Improvement Association. Mr. Holmes currently holds the Series 7, and is pursuing the Series 63 registrations with FINRA.